Octreotide vs Tesamorelin
Overview
Octreotide is primarily a hormonal peptide, while Tesamorelin is used for performance & growth.
This page compares Octreotide and Tesamorelin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Octreotide | Tesamorelin | |
|---|---|---|
| Category | Hormonal | Performance & Growth |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) | 2 mg |
| Frequency | Every 4 weeks (LAR); two to four times daily (immediate-release) | daily |
| Reported benefits | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers | Visceral fat reduction, improved body composition, GH release |
| Reported side effects | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain | Joint pain, peripheral edema |
Key differences
Primary use. Octreotide is categorised under Hormonal, while Tesamorelin falls under Performance & Growth. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Octreotide: FDA-approved. Tesamorelin: FDA-approved.
Dosing. Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)). Tesamorelin is typically dosed at 2 mg (daily).
Can you stack them?
Some protocols combine peptides, but stacking Octreotide and Tesamorelin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Octreotide and Tesamorelin?
- Octreotide is primarily a hormonal peptide, while Tesamorelin is used for performance & growth. Octreotide is FDA-approved for one or more indications, whereas Tesamorelin is FDA-approved for one or more indications.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- What is Tesamorelin used for?
- GHRH for visceral fat.
- Can you take Octreotide and Tesamorelin together?
- Some users combine peptides within a single protocol, but stacking Octreotide and Tesamorelin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Octreotide or Tesamorelin FDA-approved?
- Octreotide is FDA-approved for one or more indications. Tesamorelin is FDA-approved for one or more indications.
Read the full articles
- Octreotide — full monograph: mechanism, research, dosing & references
- Tesamorelin — full monograph: mechanism, research, dosing & references